CASI Pharmaceuticals (CASIF) Short-term Investments (2021 - 2023)

CASI Pharmaceuticals (CASIF) has 3 years of Short-term Investments data on file, last reported at $12.0 million in Q4 2023.

• Quarterly Short-term Investments rose 721.55% year-over-year to $12.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $12.0 million (up 721.55% YoY) and the FY2023 annual result came in at $12.0 million, up 721.55% from the prior year.
• Short-term Investments fell to $12.0 million in Q4 2023, from $19.9 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $19.9 billion in Q2 2023 to a low of $1.5 million in Q4 2022.
• A 3-year average of $5.0 billion and a median of $10.9 million in 2021 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments slumped 85.18% — and 2023, when it soared 721.55%.
• Tracing CASIF's Short-term Investments over 3 years: stood at $9.9 million in 2021, then tumbled by 85.18% to $1.5 million in 2022, then soared by 721.55% to $12.0 million in 2023.
• The last three Short-term Investments figures came in at $12.0 million (Q4 2023), $19.9 billion (Q2 2023), and $1.5 million (Q4 2022), per Business Quant data.